Chilblains Treatment: Podiatrist’s Guide to Cold Toe Pain (2026)

Chilblains are one of those conditions that most people have never heard of — until they get them. If you’ve ever developed painful, itchy, purple bumps on your toes after coming in from a cold, damp day, you likely experienced chilblains.

In our Michigan practice, we see chilblains during the late fall and early spring — when temperatures hover around 32–50°F and dampness is high. The condition surged in awareness during the COVID-19 pandemic, when ‘COVID toes’ — a clinically similar phenomenon — were widely reported.

What Are Chilblains?

Chilblains (medical term: pernio) are an abnormal inflammatory skin response triggered by repeated or prolonged exposure to cold, damp (but not freezing) temperatures. They manifest as small, red-to-purple inflammatory lesions most commonly on the toes, heels, and outer ankles. The condition involves pathological vasoconstriction (narrowing of blood vessels) followed by reactive vasodilation (widening), during which inflammatory fluid leaks into surrounding tissue.

Chilblains are distinct from frostbite (which requires true freezing temperatures and causes cellular ice crystal formation) and from Raynaud’s phenomenon (a related but different vascular condition affecting fingers and toes with distinct color changes). However, people with Raynaud’s are more susceptible to chilblains.

• Occur in cold, damp (not necessarily freezing) conditions — typically 32–60°F
• Most common in young to middle-aged women, though all demographics affected
• Typically develop on toes, heels, outer ankles; less commonly fingers, nose, ears
• Appear within hours of cold exposure; peak 12–24 hours after rewarming
• Seasonal: late fall, winter, early spring in northern climates
• Often recur annually in susceptible individuals

Symptoms: How to Recognize Chilblains

Chilblains have a characteristic appearance and symptom pattern that distinguishes them from other cold-related conditions:

• Color: initially red → progresses to purple or blue-purple; may become brownish as they heal
• Texture: small, discrete raised bumps or plaques on the skin surface
• Sensation: burning, stinging, intense itching — often worsening as the area warms
• Location: typically the dorsum (top) and sides of toes; heels and outer ankle borders
• Timing: symptoms appear during or shortly after rewarming from cold exposure
• Duration: individual lesions typically resolve in 2–3 weeks; recurrent with repeated cold exposure
• In severe cases: skin blistering, ulceration, and secondary infection

What Causes Chilblains? The Vascular Mechanism

The exact mechanism of chilblains involves an abnormal response to cold in the microvasculature (small blood vessels) of the skin. When exposed to cold, the body naturally vasoconstricts peripheral blood vessels to conserve core body temperature. In susceptible individuals, this vasoconstriction is exaggerated or prolonged, leading to reduced blood flow to the skin of the extremities.

When the person re-enters warmth, the blood vessels rapidly dilate (rewarm). This rapid shift from vasoconstriction to vasodilation causes plasma to leak into the surrounding tissue — producing the inflammation, swelling, and itch characteristic of chilblains. The repeated cycle of vasoconstriction and reactive hyperemia causes progressive inflammatory tissue damage with each cold exposure.

• Risk factors: female sex, low body mass index, peripheral vascular disease, Raynaud’s phenomenon, autoimmune conditions (lupus, antiphospholipid syndrome), living in cold-damp climates
• COVID-19 association: ‘COVID toes’ — chilblain-like lesions from type I interferon-mediated vasculopathy — were widely reported in 2020–2021
• Genetic susceptibility: some individuals have inherently more reactive vasomotor responses to cold

Treatment: Immediate and Long-Term

Immediate Care

• Gradually rewarm the affected area — move to a warm room and remove wet footwear
• Never apply direct heat (hot water bottle, heating pad, direct flame) — this worsens vasodilation injury
• Elevate the affected foot to reduce swelling
• Gently pat dry — avoid rubbing, which traumatizes already-inflamed skin
• Lanolin-based moisturizer protects the skin barrier and reduces moisture loss

Topical Treatments

Topical corticosteroid cream (hydrocortisone 1% OTC or higher-strength prescription) is the primary treatment for chilblain itch and inflammation. Apply to the affected skin 1–2 times daily for up to 2 weeks. Reduces the inflammatory response and relieves the burning and itching significantly. Do not apply to broken skin.

Topical nifedipine gel (where available by compounding) reduces vasoconstriction locally and has shown good efficacy in clinical studies.

Oral Medications for Severe or Recurrent Chilblains

Nifedipine (a calcium channel blocker, 20–60 mg/day extended release) is the most evidence-supported systemic treatment for severe or recurrent chilblains. It reduces vasoconstriction by relaxing vascular smooth muscle, improving circulation to the extremities and reducing the severity and duration of attacks. Side effects include headache, flushing, and ankle swelling.

Other agents used in refractory cases: pentoxifylline (improves blood rheology), oral corticosteroids (short course for severe inflammatory flares), and hydroxychloroquine (for autoimmune-associated chilblains).

Prevention: The Most Effective Treatment

Because chilblains recur with cold exposure in susceptible individuals, prevention is the cornerstone of management:

• Wear warm, waterproof, layered footwear in cold weather — moisture is as important as temperature
• Keep feet and hands dry — change socks immediately if they become damp
• Avoid prolonged exposure to cold, damp environments
• Begin nifedipine prophylaxis before the cold season in recurrent sufferers
• Avoid rapid temperature changes — warm the environment before removing cold clothing
• Maintain good overall circulation: exercise regularly, avoid tight clothing, don’t smoke
• Use moisture-wicking socks — cotton retains moisture; wool or synthetic wick it away

Chilblains vs. COVID Toes: What’s the Difference?

During the COVID-19 pandemic, a condition known as ‘COVID toes’ emerged — chilblain-like lesions on the toes and feet, often in young otherwise healthy individuals, associated with COVID-19 infection. Clinically, they appear nearly identical to classical chilblains. The proposed mechanism involves type I interferon-mediated endothelial inflammation and microthrombi in dermal vessels rather than the classical cold-damp trigger.

Differentiating classical chilblains from COVID toes: COVID toes often occur in warm weather (atypical for chilblains), may occur in younger individuals without cold exposure history, and may be associated with other COVID symptoms or a positive PCR test. Skin biopsy shows similar histological patterns. Treatment is the same as for classical chilblains.

When Shoes Aren’t Enough — Dr. Tom’s Top 9 Orthotics

About 30% of patients I see for foot pain need MORE than a great shoe — they need a structured insole. Below: my complete 2026 orthotic ranking with pros, cons, and the specific patient I’d give each one to.

Frequently Asked Questions: Chilblains Treatment

How long do chilblains last?

Individual chilblain lesions typically resolve within 2–3 weeks with proper treatment and protection from further cold exposure. However, if cold exposure continues, new lesions develop and existing ones worsen. Without treatment, severely inflamed lesions can persist 4–6 weeks. In recurrent annual sufferers, the condition appears each cold season for years.

Should I pop chilblain blisters?

No — do not rupture chilblain blisters. The blister fluid is sterile and provides a natural barrier against infection. Rupturing the blister creates an open wound that is vulnerable to bacterial infection, particularly dangerous in people with diabetes or vascular disease. If a blister ruptures on its own, keep it clean and covered with a sterile dressing.

Are chilblains contagious?

No — chilblains are not contagious and cannot be transmitted from person to person. They are a non-infectious inflammatory response to cold in the individual’s own vascular system. No precautions for contagion are necessary.

Can diet help prevent chilblains?

Some evidence suggests that poor circulation associated with low body weight and nutritional deficiencies (particularly iron and vitamin D) increases susceptibility to chilblains. A nutritionally complete diet, maintaining a healthy BMI, avoiding smoking (which dramatically impairs peripheral circulation), and limiting caffeine (which causes vasoconstriction) may reduce susceptibility. No specific dietary intervention has strong clinical evidence.

When should I see a podiatrist for chilblains?

See a podiatrist if: blistering or skin breakdown has occurred; the chilblains are not improving after 3 weeks; you have diabetes or peripheral vascular disease (higher risk of complications); symptoms appear without obvious cold exposure trigger; or you have recurrent chilblains every winter and want a preventive plan.

Sources

• Cappel JA, Wetter DA. Clinical Characteristics, Etiologic Associations, Laboratory Findings, Treatment, and Proposal of Diagnostic Criteria of Pernio. Mayo Clin Proc. 2014;89(2):207–215.
• Kwinter J, Pelletier J, Khambalia A, et al. High-Potency Steroid Use in Children With COVID-19–Associated Pernio. Pediatr Dermatol. 2021;38(2):337–344.
• Matar S, et al. Comparison of Chilblain Cases Occurring During and Before the COVID-19 Pandemic. JAMA Dermatol. 2020;156(12):1363–1364.
• Drago F, et al. Nifedipine in Pernio/Chilblain: A Systematic Review. Int J Dermatol. 2024;63(4):487–494.
• Simon T, et al. COVID-19 Pandemic Lockdown-Associated Chilblains: Mimic or Real? Int J Dermatol. 2021;60(7):809–817.